key: cord-0751233-uunfq130
authors: Shrestha, Nabin K.; Shrestha, Priyanka; Burke, Patrick C.; Nowacki, Amy S.; Terpeluk, Paul; Gordon, Steven M.
title: Coronavirus Disease 2019 (COVID-19) Vaccine Boosting in Previously Infected or Vaccinated Individuals
date: 2022-04-27
journal: Clin Infect Dis
DOI: 10.1093/cid/ciac327
sha: 2b6c5e47ff82b0694b4cab382a6ac65e28831b29
doc_id: 751233
cord_uid: uunfq130

BACKGROUND: The purpose of this study was to evaluate whether boosting previously infected or vaccinated healthcare personnel with a vaccine developed for an earlier variant of SARS-CoV-2 protects against the Omicron variant. METHODS: Employees of Cleveland Clinic previously infected with or vaccinated against COVID-19, and working in Ohio the day the Omicron variant was declared a variant of concern, were included. The cumulative incidence of COVID-19 was examined over two months during an Omicron variant surge. Protection provided by boosting (analyzed as a time-dependent covariate) was evaluated using Cox proportional hazards regression. Analyses were adjusted for time since proximate SARS-CoV-2 exposure as a time-dependent covariate. RESULTS: Among 39 766 employees, 8037 (20%) previously infected and the remaining previously vaccinated, COVID-19 occurred in 6230 (16%) during the study. Risk of COVID-19 increased with time since proximate SARS-CoV-2 exposure, and boosting protected those >6 months since prior infection or vaccination. In multivariable analysis, boosting was independently associated with lower risk of COVID-19 among those vaccinated but not previously infected (HR, .43; 95% CI, .41-.46) as well as those previously infected (HR, .66; 95% CI, .58-.76). Among those previously infected, receiving 2 compared to 1 dose of vaccine was associated with higher risk of COVID-19 (HR, 1.54; 95% CI, 1.21-1.97). CONCLUSIONS: Administering a COVID-19 vaccine not designed for the Omicron variant, >6 months after prior infection or vaccination, protects against Omicron variant infection in those previously infected or vaccinated. There is no evidence of an advantage to administering more than 1 dose of vaccine to previously infected persons.

By the time the Delta variant of severe acute respiratory syndrome-associated coronavirus 2 2 time-dependent covariate). Employees who had not developed COVID-19 were censored at the end of the 11 study follow-up period (28 January 2022). Those whose employment was terminated during the study 12 period before they had COVID-19 (216 subjects) were censored on the date of termination of 13 employment. Curves for the non-boosted were based on data for as long as the booster status remained 14 "non-boosted". Curves for the boosted were based on data from the date the booster status changed to 15 "boosted", until the study end date. 16

To evaluate the effect of time since proximate SARS-CoV-2 exposure on risk of COVID-19, 17

Simon-Makuch hazard plots comparing the cumulative incidence of COVID-19 for groups stratified by 18 time since proximate SARS-CoV-2 exposure were plotted separately for those previously infected and 19 those vaccinated but not previously infected. Subjects were censored on the date they were terminated as 20 in the primary analysis. Time since proximate SARS-CoV-2 exposure could change for any subject any 21 day over the course of the study if they received a vaccine during the study, and subjects moved from one 22 subgroup to another as they crossed the limits of the time group strata. time-dependent covariates. For the latter, the number of vaccine doses was evaluated as a time-dependent 2 covariate (as it could change for any subject on any day of the study). 3

Multivariable Cox proportional hazards regression models were fitted to examine associations of 4 various variables with time to COVID-19, separately for those previously infected and those vaccinated 5 but not previously infected. Where included, boosting, time since proximate SARS-CoV-2 exposure, time 6 since prior infection, and number of vaccine doses were included as time-dependent covariates [13] . 7

These models were also explored in subsets divided by time since prior infection (for those previously 8 infected) and time since second vaccine dose (for those vaccinated but not previously infected). 9

The analysis was performed by N. K. S. and A. S. N. using the survival package and R version 

Of 39 766 employees included in the study, 8037 (20%) were previously infected and 31 729 13 (80%) vaccinated but not previously infected. By the end of the study, 26 176 (66%) were boosted. 14 Altogether, 6230 employees (16%) acquired COVID-19 during the 9 weeks of the study. 15

Baseline characteristics 16 Table 1 shows the characteristics of subjects grouped by type of prior SARS-CoV-2 exposure at 17 the start of the study. The median duration since prior SARS-CoV-2 exposure was, 331 days (IQR 228-18 363 days) for those previously infected, and 275 days (IQR 228-283 days) for those vaccinated but not 19 previously infected. 20 Table 2 shows the characteristics of subjects grouped by their boosting status by the end of the 21 study. For those boosted, the median time to being boosted was 16 days prior to the study start date (IQR 22 -38 to 6 days). 23

were either previously infected, or vaccinated but not previously infected 2 Figure 1 compares the cumulative incidence of COVID-19 stratified by type of prior SARS-CoV-3 2 exposure and vaccine boosting status. Among persons vaccinated but not previously infected, the 4 cumulative incidence of COVID-19 was significantly lower for those boosted compared to those not 5 boosted. However, among those previously infected, the cumulative incidence of COVID-19 did not 6 differ between the boosted and the non-boosted in an unadjusted comparison. 7

Time since proximate SARS-CoV-2 exposure 8 Figure 2 shows the risk of COVID-19 stratified by time since proximate SARS-CoV-2 exposure, 9

separately for those previously infected, and those vaccinated but not previously infected. 10

For those previously infected, the risk of COVID-19 was lowest for proximate SARS-CoV-2 11 exposure within the preceding 6 months. Proximate SARS-CoV-2 exposure between 6-9 months had a 12 higher risk, and proximate SARS-CoV-2 exposure 9 months or longer in the past had an even higher risk. 13

For those vaccinated but not previously infected, the risk of COVID-19 was higher for proximate 14 SARS-CoV-2 exposure 3-6 or 6-9 months previously compared to proximate SARS-CoV-2 exposure 15 within the preceding 3 months, suggesting that protection against the Omicron variant from two doses of 16 an mRNA vaccine wanes after 3 months. Surprisingly, proximate SARS-CoV-2 exposure 9-12 months 17 previously had a lower risk of COVID-19 than proximate SARS-CoV-2 exposure 3-9 months previously, 18 and a similar risk to proximate SARS-CoV-2 exposure within the preceding 3 months. 19

Among previously infected persons who did not subsequently get vaccinated, the risk of COVID-21 19 was substantially higher for those infected at least 6 months previously than those infected within 6 22 months ( Figure 3 ). Among those infected at least 6 months previously, those vaccinated (1 or more doses) 23 after COVID-19 had lower risk of COVID-19 than those not. Among those previously infected within 6 24

months, risk of COVID-19 for those subsequently vaccinated did not differ significantly from those who 1 remained unvaccinated. A single infection within the <6 months and vaccinated group would make the 2 cumulative incidence of COVID-19 in that group the same as that of the <6 months and unvaccinated 3 group (note the small at risk sample size). Notably, those previously infected within the preceding 6 4 months and subsequently unvaccinated still had a risk of COVID-19 that was significantly lower than that 5 of those previously infected more than 6 months earlier and subsequently vaccinated. 6

Among previously infected individuals, those who received 1 dose of vaccine had a significantly 8 lower risk of COVID-19 than those who received no vaccine, but those who received 2 doses had a higher 9 risk of COVID-19 than those who received a single dose and a risk that was no lower than those who 10 received no vaccine ( Figure 4 ). Those who received 3 doses appeared to have a lower risk than those who 11 received no vaccine, but a higher risk than those who received a single dose. 12

Boosting with a COVID-19 vaccine designed for an earlier variant was associated with 14 significantly reduced risk of infection with the Omicron variant in multivariable Cox proportional hazards 15 regression analyses, among people vaccinated but not previously infected (Table 3 ) or previously infected 16 (Table 4) , for whom it was more than 6 months past their prior infection or vaccination. 17

When the effect of number of vaccine doses in previously infected individuals was analyzed in 18 multivariable analysis, there was no advantage to more than 1 dose of vaccine, and those who received 2 19 doses were at significantly higher risk of getting COVID-19 than those who received a single dose (Table  20 5), supporting the findings of the unadjusted comparison visually depicted in figure 4 . 21

This study corroborates findings from earlier studies that natural immunity from prior infection is 23 more robust than immunity acquired through vaccination [11, 17, 18] , and additionally finds that 24

individuals previously infected with a pre-Omicron variant of SARS-CoV-2 retain substantial protection 1 against the Omicron variant for at least 6 months in the absence of vaccination. 2

This study found that time since proximate SARS-CoV-2 exposure was an important risk factor 3 for COVID-19 among both previously infected and previously vaccinated individuals. Individuals 4 previously infected with a pre-Omicron variant enjoy some protection against the Omicron variant for up 5 to 6 months, with subsequent waning of protection. Among those vaccinated but not previously infected, 6 time since proximate SARS-CoV-2 exposure greater than 3 months was associated with a higher risk of 7 COVID-19 than time since proximate SARS-CoV-2 exposure less than 3 months, suggesting waning of 8 vaccine-induced immunity after 3 months. The association of lower risk of COVID-19 with time since 9

proximate SARS-CoV-2 exposure of 9-12 months compared to 3-9 months requires careful interpretation. 10

Given the time period in which the study was conducted, this anomalous finding could possibly be 11 explained by the fact that those with proximate SARS-CoV-2 exposure (i.e. vaccination) 9-12 months 12 previously were those who would have faced the Delta variant within the preceding 3 months with 13 

This study also found that among previously infected individuals, receipt of a single dose of 21 vaccine provides protection against COVID-19 compared to receipt of no doses of vaccine, but that 22 receipt of more than 1 dose of vaccine provides no additional protection beyond that acquired by receipt 23 of a single dose. Surprisingly, receipt of 2 doses of vaccine was associated with higher risk of COVID-19 24 than receipt of a single dose. This last finding raises the intriguing possibility that a second dose of 25 vaccine given shortly after the first in persons with pre-existing natural immunity might nullify the 26

protection that a single dose of vaccine would otherwise provide. If so, it will have to bear out in other 1 studies that can adequately evaluate this association. 2

The strengths of our study include its large sample size and a study start date that resulted in all 3 prior infections being pre-Omicron variant infections and the vast predominance of incident infections 4 being Omicron variant infections. Given that this was a study among employees of a health system, that 5 recognized very early the critical importance of maintaining an effective workforce during the pandemic, 6

we had an accurate accounting of who had COVID-19, when they were diagnosed with COVID-19, who 7 received a COVID-19 vaccine, and when they received it. The time-to-event analysis design allowed for 8 important covariates that change over time to be adjusted in a time-dependent manner. 9

The study has its limitations. Individuals with unrecognized asymptomatic prior infections would 10 have been misclassified as previously uninfected, resulting in underestimating the protective effect of 11 prior infection. Many asymptomatic incident infections were probably missed. There is little reason to 12 suppose, however, that they would have been missed in the various groups at rates disproportionate 13 enough to change the directionality of the study's findings. Because our employee health symptom-14 monitoring processes were overwhelmed by disease volume during the Omicron phase of the pandemic, 15

we were unable to distinguish between symptomatic and asymptomatic infections and had to limit our 16 analyses to all detected infections. We did not have a way to adjust for behavioral differences and 17 household exposures, both of which can strongly influence risk of COVID-19. Our study of healthcare 18 personnel included no children and few elderly subjects, and the majority would not have been 19

immunocompromised. Lastly, knowing that the Omicron variant causes milder infection than the Delta 20 variant, the clinical impact of protection from severe infection with vaccine boosting would be smaller 21 than the protective effect on infections overall that this study found. 22

In conclusion, natural immunity from prior COVID-19 provides substantial protection against the 23

Omicron variant for at least 6 months even in the absence of a vaccine. There is little to be gained by the day the Omicron variant was first declared a variant of concern. Point estimates and 95% confidence 4 intervals are jittered along the x-axis to improve visibility. Those previously infected are represented in 5 blue and those vaccinated but not previously infected in red. Boosting was a time-dependent covariate 6 whose value changed from "non-boosted" to "boosted" 7 days after receipt of a vaccine booster. Those 7 boosted are represented by bold lines and those who remained non-boosted by dashed lines. 8 by time since proximate SARS-CoV-2 exposure as a time-dependent covariate. The left panel shows the 10 cumulative incidence for those previously infected and the right one for those vaccinated but not 11 previously infected. Day zero was 26 November 2021, the day the Omicron variant was declared a variant 12 of concern. Point estimates and 95% confidence intervals are jittered along the x-axis to improve 13 visibility. Receipt of a vaccine booster (as a time-dependent covariate) was considered an exposure to 14 SARS-CoV-2 and would result in data for that subject to move to the '<3 m' group 7 days after the date 15 of the booster. 16 

Protection of BNT162b2 vaccine booster against 2 COVID-19 in Israel

Effectiveness of a third dose of the BNT162b2 mRNA COVID-4 19 vaccine for preventing severe outcomes in Israel: an observational study

Protection against COVID-19 by BNT162b2 Booster 7 across Age Groups

Preliminary modeling estimates of the relative 9 transmissibility and immune escape of the Omicron SARS-CoV-2 variant of concern in South 10

04.22268721v1, preprint: not peer reviewed

Omicron SARS-CoV-2 13 variant: Unique features and their impact on pre-existing antibodies

The hyper-transmissible SARS-CoV-2 Omicron variant 16 exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism

Increased risk of SARS-CoV-2 reinfection 19 associated with emergence of the Omicron variant in South Africa. medRxiv, doi: 20 2021.11.11.21266068v2, preprint: not peer reviewed

Using time dependent covariates and time dependent 1 coefficients in the Cox model

Modeling survival data: extending the Cox model

Core Team. R: A Language and environment for statistical computing

Prediction of long-term kinetics of vaccine-elicited neutralizing 8 antibody and time-varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by 9 clinical endpoint. medRxiv, doi: 2021.09.23.21263715v1, preprint: not peer reviewed

Comparing SARS-CoV-2 natural immunity to vaccine-12 induced immunity: reinfections versus breakthrough infections. medRxiv

COVID-19 Cases and hospitalizations by COVID-19 15 vaccination status and previous COVID-19 diagnosis -California